Table 1.
Ref. | Type of TB | Setting, US state(s) | Sample year(s) | Sample size | Hospitalization | Physician fees, inpatient | Physician fees, outpatient | Outpatient case management | Laboratory and imaging tests | Medications |
---|---|---|---|---|---|---|---|---|---|---|
[20] | Drug-susceptible | 16 statesa | 1990 | n/s | 26,900b | 3800 | 6200 | |||
MDR | 21,500 | |||||||||
[21] | Drug-susceptible | IA | 1991 | n/a | 10,100 | 600 | 2200 | 800 | ||
[14] | Drug-susceptible | CA, MS, NJ | 1992 | 178 | 1600 | 1200 | ||||
[22] | Drug-susceptible | PA | 1992 | 18 | 45,400 | |||||
[23] | Drug-susceptible | MD | 1992–94 | n/s | 600 | 3100 | 1200 | 1300 | ||
[24] | Drug-susceptible | MA | 1993 | n/a | 1300 | |||||
MDR | 16,900 | |||||||||
[25] | Drug-susceptible | IL | 1993–94 | 90 | 3400 | 1300 | ||||
[5] | Drug-susceptible | CA | 1995 | 300 | ||||||
MDR | CA | 1995 | 1200 | |||||||
[10] | Drug-susceptible | 7 statesc | 1995–96 | 733 | 19,300 | |||||
[26] | MDR | 7 statesc | 1995–96 | 13 | 43,300 | 4000 | 34,100 | |||
[8] | Drug-susceptible | US | 2006 | 8800 | 18,300b | |||||
[27] | Drug-susceptible | OR | 2006 | 42 | 8000 | |||||
[28] | MDR | CA, NY, TX | 2005–07 | 130 | 62,600 | |||||
[6] | Drug-susceptible | NC | 2008–10 | 99 | 1400 | 1400 | 300 | |||
[29] | MDR | US | 2009 | n/a | 11,600 | |||||
[30] | Drug-susceptible | TN | 2010 | n/a | 2900 | 500 | ||||
[4] | Drug-susceptible | US | 2011 | n/a | 200 | |||||
[31] | Drug-susceptible | US | 2014 | n/a | 300 |
n/s not specified, n/a not applicable (i.e., estimates not based on a sample of cases, but on administrative data)
aAZ, CA, CO, FL, MA, ME, NH, NJ, NV, NY, OR, PA, SC, VT, WA, WI
bThe reported value was per hospitalization episode, and was adjusted to a per-case patient estimate using the utilization assumptions detailed in Additional file 3
cCA, GA, IL, MS, NY, SC, TX